Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine Titration Guided by Hs-CRP Targets on Cardiovascular Events in Very-High-Risk Coronary Heart Disease Patients After PCI
NCT07920133Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of colchicine in coronary artery disease (CAD) and atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Major Adverse Cardiovascular Events at 18 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07920133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920133.